32
Participants
Start Date
July 31, 2006
Primary Completion Date
March 31, 2011
Study Completion Date
March 31, 2011
bortezomib
Patients will be treated with bortezomib at 1.3mg/m\^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
dexamethasone
Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
doxorubicin HCl liposome
Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m\^2 on Day 4 every 28 days (cycle).
Arena Oncology Associates, Lake Success
Lancaster Cancer Center, Ltd., Lancaster
Oncology-Hematology Associates, P.A., Clinton
Cancer Specialists of Tidewater, Ltd., Chesapeake
Northwest Georgia Oncology Centers, PC, Marietta
Northeast Georgia Cancer Care, Athens
Augusta Oncology Associates, PC, Augusta
Advanced Medical Specialties, Miami
The West Clinic, Memphis
Mid Ohio Oncology/Hematology, Inc., Columbus
Tri-County Hematology and Oncology Associates, Canton
Hematology Oncology Centers of the Northern Rockies, PC, Billings
North Idaho Cancer Center, Coeur d'Alene
Wilshire Oncology Medical Group, Inc., La Verne
Medical Oncology & Hematology, Waterbury
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
Accelerated Community Oncology Research Network
OTHER